New treatment for lung fibrosis related to scleroderma
Official title: TT-036 for the treatment of scleroderma-associated pulmonary fibrosis
Funded at Thendor Therapeutics LLC · NIH-11006098 · Data updated 2026-11-12
This study is looking at a new treatment made from collagen that could help people with lung fibrosis caused by scleroderma, aiming to improve their health and quality of life more effectively than current options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thendor Therapeutics LLC NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project start | September 5, 2024 |
| Project end | September 4, 2025 |
| Funding year | 2024 |
| Award (this year) | $389,754 |
| NIH project number | 1R41HL176277-01 |
| Project ID | NIH-11006098 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with scleroderma who are experiencing lung fibrosis.
✕Less likely to help
Patients with lung fibrosis not related to scleroderma or those who have already undergone lung transplantation may not benefit from this research.
What this research studies
This research investigates a novel peptide derived from collagen XVIII that may help treat lung fibrosis associated with scleroderma. The approach focuses on its anti-fibrotic effects observed in both animal models and human pre-clinical studies. By targeting the underlying mechanisms of fibrosis, the research aims to provide a more effective treatment option compared to existing therapies that only slow disease progression. Patients with severe lung fibrosis may benefit from this innovative treatment, which could improve their quality of life and health outcomes.
Why it matters
Potential benefit: If successful, this research could lead to a new therapy that effectively reduces lung fibrosis and improves survival rates for patients with scleroderma.
How similar studies have gone: While there have been studies on various treatments for lung fibrosis, this specific approach using collagen-derived peptides is novel and has not been extensively tested in clinical settings.
Where this research is happening
-
Thendor Therapeutics LLC
Lexington, United States Active
Researchers
- Principal investigator: Feghali-Bostwick, Carol a. — Thendor Therapeutics LLC
- Study coordinator: Feghali-Bostwick, Carol a.
Related research
Other NIH-funded projects on the same topics.
-
New mouse and human lung models to study how T cells drive scleroderma-related lung fibrosis
Aims to understand how specific T cell types contribute to lung scarring in scleroderma by using advanced mouse and human lung models.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
-
Alveolar Cell Dysfunction in Pulmonary Fibrosis: Using SFTPC Mutations to Find New Targets
This grant explores how rare SFTPC mutations in alveolar cells may drive IPF and seeks new molecular targets to improve treatment.
-
Iron and scar-forming cells in the lungs (IPF)
Researchers are exploring how iron in the lungs may drive the scarring seen in idiopathic pulmonary fibrosis and whether this could lead to new therapies.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.